Stockreport

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Cardiol Therapeutics Inc. - Class A Common Shares  (CRDL) 
PDF Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interv [Read more]